Full Title
STUDY MER-XMT-1660-1 A PHASE 1, FIRST-IN-HUMAN, DOSE ESCALATION AND EXPANSION, MULTICENTER STUDY OF XMT-1660 IN PARTICIPANTS WITH SOLID TUMORSPurpose
The purpose of this study is to find the highest dose of the investigational drug XMT-1660 that can be given safely in people with advanced triple-negative breast cancer (TNBC) that persists despite prior chemotherapy. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
TNBC frequently expresses a protein called B7-H4, which contributes to the growth of cancer cells. By blocking this protein, XMT-1660 may help slow or stop TNBC growth. It is given intravenously (by vein) every 3 weeks.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have TNBC that has grown beyond its original location or metastasized to other parts of the body despite no more than three prior regimens of chemotherapy.
- The serious side effects of previous treatments must go away before XMT-1660 is given.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Nour Abuhadra at 646-888-4451.